Tracheobronchomalacia (TBM) is a disease of excessive collapse of the primary airways resulting from intrinsic weakness or extrinsic compression. While infantile TBM typically regresses in severity over time, adult-phenotype TBM is more often persistent and progressive.
Our group has previously had success treating infantile TBM using a bioresorbable, 3D-printed external splint. 4, 5 This device generally has limitations in its application to acquired disease because of its temporary design. However, we describe a patient-specific, 3D-printed external tracheal splint for treatment of TBM, with modifications to device design and biomaterial selection yielding a biopermanent option for patients with adult-phenotype TBM.
Methods | The patient was a young woman with severe autism, thoracic scoliosis, and acquired tracheomalacia due to compression between a high-riding innominate artery and the thoracic spine within a narrowed thoracic inlet. Her disease progressed such that she experienced repeated cardiopulmonary arrests despite pharmacologic paralysis, mechanical ventilation, and continuous sedation for over 40 days. Previous attempts at treatment included manubriectomy, aortopexy, and innominate artery reimplantation. Endoscopic examination demonstrated continued severe, focal, compressive tracheomalacia (Figure, A [left] ). Discontinuation of care was recommended by her physicians.
We hypothesized that an external splint would be effective in treating her acquired TBM. Such a device must provide long-term stiffness to maintain airway patency while avoiding fatigue failure due to repetitive-motion forces. Design modifications compared with previously used polycaprolactone (PCL) splints are summarized in the Table and included removing the bellowed topography to diffuse contact forces, thinning the wall structure to lighten the device, and increasing the open angle of the splint to facilitate placement (Figure, B) .
Clearance for use of the device was obtained from the University of Michigan institutional review board and the US Food and Drug Administration. Using the patient's computed tomography (CT) scan imported into computer-aided design software (Mimics, version 16.0; Materialise), a model of the patient's respiratory, skeletal, and vascular anatomy was generated (Figure, C and D) . Splint geometric design parameters were determined from measurements of the affected tracheal segment and used to generate the device design (MATLAB, Mathworks). The splint stereolithography model was digitally fit over the airway for design validation. The device was 3D printed using polyetherketoneketone (PEKK) (OXPEKK; Oxford Performance Materials) (Figure, E) . PEKK was chosen for its material properties, superior to those of PCL for a non-resorbable implant, and for its suitability to manufacture the device via 3D printing (Table) .
Implantation was performed via a midline sternotomy approach by placing the splint around the affected trachea and suspending the trachea within the splint using polypropylene sutures ( Discussion | We demonstrate successful treatment of lifethreatening acquired tracheomalacia with a 3D-printed biopermanent tracheal splint in a patient for whom all prior therapeutic approaches had failed. This first-in-human use of a novel device demonstrates promising results in arresting severity and alleviating morbidity of adult-phenotype TBM. 
COMMENT & RESPONSE

Cetuximab and Radiotherapy in Laryngeal Preservation
To the Editor We read with interest the article "Cetuximab and Radiotherapy in Laryngeal Preservation for Cancers of the Larynx and Hypopharynx: A Secondary Analysis of a Randomized Clinical Trial" by Bonner et al. 1 We congratulate the authors on their phase 3 clinical trial, however, some potentially misleading ambiguities can be noticed in their article. First, laryngeal and hypopharyngeal cancers are different neoplasms with heterogeneous behavior, prognosis, and possible surgical treatments.
2 When analyzing oncological and/or functional outcomes among patients treated for hypopharyngeal or laryngeal carcinoma, the results should be analyzed separately for the different subgroups.
Second, in the article by Bonner et al, 1 tumor and node stages are more advanced in the radiotherapy alone (RT) group than in the cetuximab plus radiotherapy (CRT) group (the frequency of T4 stage is 35.9% in RT group and 27.8% in the CRT group, while the frequency of N2-3 stages is 51.3% and 45.6% in the 2 groups, respectively). 1 This is an important bias since T4 and N2-3 stages are the major determinants of tumor locoregional control. 2 Considering the difference in laryngeal preservation (LP) rates between RT and CRT groups is "encouraging" but not statistically significant in Bonner and colleagues' article, 1 such dissimilarity in T4 and N2-3 stages likely affects the authors' results and conclusions. Third, the authors report their statistics on locoregional control at 1-and 2-year follow-up, which is extremely short (a 5-year follow-up is generally recommended).
1,3 This is even more important when considering that the authors report a "collapse" in locoregional control between the first and the second year of follow-up. 1 Drawing oncological conclusions after such a short follow-up may be hazardous. Finally, radiotherapy with concomitant cisplatin has been proven to attain the highest LP rate and is currently the gold standard in organ preservation protocols for stages III and IV laryngeal and/or hypopharyngeal carcinomas. 3, 4 Comparing LP rate of CRT with a treatment (RT) that is not considered the current standard of care for LP in locally advanced laryngeal and/or hypopharyngeal cancer raises some important questions in terms of ethics and patient's informed consent. If the study's purpose is to examine cetuximab as an alternative concurrent agent to cisplatin for LP, CRT should be compared with cisplatin concurrent radiochemotherapy in terms of oncological and/or functional results and adverse effects. Considering that overall survival for patients with laryngeal cancer has decreased in the United States from 1975 to 2010, 5 great care should be paid before introducing new LP protocols for laryngeal and/or hypopharyngeal cancers.
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